Examining Hyperhidrosis (Excessive Sweating): A Managed Markets Update on New Treatments, Featuring a Patient Perspective

https://www.pharmacytimes.org/on-demand/examining-hyperhidrosis-excessive-sweating-a-managed-markets-update-on-new-treatments-featuring-a-patient-perspective

Related Videos

Related Content

Advertisement

November 23rd 2024

Viltolarsen Slows DMD Progression in Small Study

Hayden E. Klein

Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).

November 21st 2024

Frameworks for Advancing Health Equity: Wellness Way

Giuliana Grossi

The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.

November 23rd 2024

Edentulism May Heighten Sleep Apnea Risk

Jared Kaltwasser

A systematic review has found a potential link between edentulism and sleep apnea risk, although the authors said differences in study designs prohibited a meta-analysis.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 23rd 2024

Health Equity & Access Weekly Roundup: November 23, 2024

Giuliana Grossi

Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.

November 22nd 2024

FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy

Marco Meglio

The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.

Related Content

Advertisement

November 23rd 2024

Viltolarsen Slows DMD Progression in Small Study

Hayden E. Klein

Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).

November 21st 2024

Frameworks for Advancing Health Equity: Wellness Way

Giuliana Grossi

The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.

November 23rd 2024

Edentulism May Heighten Sleep Apnea Risk

Jared Kaltwasser

A systematic review has found a potential link between edentulism and sleep apnea risk, although the authors said differences in study designs prohibited a meta-analysis.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 23rd 2024

Health Equity & Access Weekly Roundup: November 23, 2024

Giuliana Grossi

Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.

November 22nd 2024

FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy

Marco Meglio

The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.